Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Earnings for Xenon Pharmaceuticals Inc. (XENE)
Earnings in 2023 (TTM): $-182,685,000
According to Xenon Pharmaceuticals Inc.'s latest financial reports the company's current earnings (TTM) are $-182,685,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Xenon Pharmaceuticals Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-182,685,000 | $-182,393,000 |
| 2022 | $-125,255,000 | $-125,373,000 |
| 2021 | $-78,888,000 | $-78,882,000 |
| 2020 | $-29,094,000 | $-28,837,000 |
| 2019 | $-41,618,000 | $-41,595,000 |
| 2018 | $-34,497,000 | $-34,497,000 |
| 2017 | $-30,704,000 | $-30,704,000 |
| 2016 | $-22,997,000 | $-22,997,000 |
| 2015 | $-15,752,000 | $-15,752,000 |
| 2014 | $13.02 M | $13.02 M |
| 2013 | $12.03 M | $12.03 M |
| 2012 | $-4,301,000 | $-4,301,000 |
| 2011 | $-11,992,000 | $-11,992,000 |